X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs TTK HEALTHCARE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA TTK HEALTHCARE NATCO PHARMA/
TTK HEALTHCARE
 
P/E (TTM) x 18.9 36.7 51.6% View Chart
P/BV x 18.1 6.8 268.3% View Chart
Dividend Yield % 0.6 0.4 146.8%  

Financials

 NATCO PHARMA   TTK HEALTHCARE
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
TTK HEALTHCARE
Mar-14
NATCO PHARMA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs877663 132.2%   
Low Rs424399 106.1%   
Sales per share (Unadj.) Rs223.4535.6 41.7%  
Earnings per share (Unadj.) Rs31.115.9 194.8%  
Cash flow per share (Unadj.) Rs40.320.0 201.1%  
Dividends per share (Unadj.) Rs5.004.00 125.0%  
Dividend yield (eoy) %0.80.8 102.1%  
Book value per share (Unadj.) Rs219.5137.6 159.5%  
Shares outstanding (eoy) m33.077.77 425.6%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.91.0 293.5%   
Avg P/E ratio x20.933.3 62.8%  
P/CF ratio (eoy) x16.126.5 60.9%  
Price / Book Value ratio x3.03.9 76.7%  
Dividend payout %16.125.1 64.2%   
Avg Mkt Cap Rs m21,5044,127 521.0%   
No. of employees `000NA1.7 0.0%   
Total wages/salary Rs m1,128607 185.9%   
Avg. sales/employee Rs ThNM2,436.7-  
Avg. wages/employee Rs ThNM355.2-  
Avg. net profit/employee Rs ThNM72.5-  
INCOME DATA
Net Sales Rs m7,3894,162 177.5%  
Other income Rs m16761 273.0%   
Total revenues Rs m7,5564,223 178.9%   
Gross profit Rs m1,793197 909.8%  
Depreciation Rs m30432 960.3%   
Interest Rs m36630 1,224.7%   
Profit before tax Rs m1,290197 655.7%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m30973 424.0%   
Profit after tax Rs m1,027124 829.2%  
Gross profit margin %24.34.7 512.5%  
Effective tax rate %23.937.0 64.7%   
Net profit margin %13.93.0 467.1%  
BALANCE SHEET DATA
Current assets Rs m3,6811,629 226.0%   
Current liabilities Rs m3,1231,058 295.2%   
Net working cap to sales %7.613.7 55.1%  
Current ratio x1.21.5 76.6%  
Inventory Days Days8930 300.5%  
Debtors Days Days5934 174.7%  
Net fixed assets Rs m7,685556 1,381.5%   
Share capital Rs m33178 425.6%   
"Free" reserves Rs m6,670878 759.4%   
Net worth Rs m7,2591,069 678.8%   
Long term debt Rs m955159 601.7%   
Total assets Rs m11,9572,399 498.3%  
Interest coverage x4.57.6 59.7%   
Debt to equity ratio x0.10.1 88.6%  
Sales to assets ratio x0.61.7 35.6%   
Return on assets %11.76.4 181.8%  
Return on equity %14.211.6 122.2%  
Return on capital %20.718.5 112.3%  
Exports to sales %39.40.8 4,978.2%   
Imports to sales %5.71.4 406.9%   
Exports (fob) Rs m2,90833 8,838.3%   
Imports (cif) Rs m42158 722.5%   
Fx inflow Rs m3,44533 10,472.3%   
Fx outflow Rs m70363 1,112.2%   
Net fx Rs m2,743-30 -9,054.5%   
CASH FLOW
From Operations Rs m1,440127 1,137.7%  
From Investments Rs m-1,089-146 746.0%  
From Financial Activity Rs m-35322 -1,610.5%  
Net Cashflow Rs m-13 -59.6%  

Share Holding

Indian Promoters % 52.0 65.4 79.6%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 3.7 211.9%  
FIIs % 16.6 5.2 319.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 25.8 100.8%  
Shareholders   25,395 12,723 199.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Up; ONGC & Tata Steel Top Gainers(Closing)

Indian share markets ended the day on a strong note. At the closing bell, the BSE Sensex finished higher by 262 points. While, the NSE Nifty finished up by 91 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


May 25, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS